When I think about the future, I think we have identified two things that are important to think about: the first one being how can medtech manufacturers partner with hospitals to help with their data strategy and AI strategy.

Hospitals today have a lot more data available to them. They are doing more to collect data to be able to track clinical outcomes as well as their own financial outcomes. And we have also seen that therapies today have more data-enabled components. So, whether that’s a chip that can track your heart rate or a neuro-modulation implant that can track procedures or something else - with the amount of data available to hospitals - it isn’t yet clear to them how best they can use this data to drive clinical as well as financial outcomes at their hospitals.

We have seen a lot of investment in resources in the US, but we also know there are big emerging healthcare markets like Latin American and Asia-Pacific. The issues and the healthcare needs of those markets is going to be different than what we have seen in the US, and the resources that are going to be available to the medtech manufacturers will be different in those areas. So, the understanding that non-clinical stakeholder engagement and the partnership and resources that are provided are going to need to account for the local context for what is needed and what is available. I think this is going to be very important for future engagement.

Watch Other Videos in this Series:

Why are non-clinical stakeholders Important to Medtech Companies?

How are Medtech Companies Adapting to Better Engage with Non-Clinical Stakeholders?


Check out our new eModule: Non-Clinical Stakeholder Engagement in Medtech.


A look ahead: Medical aesthetics market recovery in 2021 and beyond

View Now